Skip to main content
Premium Trial:

Request an Annual Quote

NanoDetection Technology Raises $2.3M in Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoDetection Technology and CincyTech today announced that NDT has completed a Series A financing round raising $2.3 million.

The round was oversubscribed as NDT had targeted $2 million.

In total, 21 investors participated in the round. CincyTech led the round with an investment of $400,000 and brought in half a dozen investors into the deal, it and NDT said. Southern Ohio Creates Companies invested $100,000.

Proceeds from the Series A round are expected to fund its clinical trials and plans to get clearance from the US Food and Drug Administration for a test for Staphylococcus aureus. The test is expected to become available in late 2013.

NDT has developed a rapid and cost-effective point-of-care IVD test platform for the detection of pathogens including MRSA, E. coli, salmonella, and listeria, as well as for DNA and other biomarker-based tests, it and CincyTech said.

NDT had been based in Knoxville, Tenn., but moved to Cincinnati last fall. Joel Ivers became its CEO in July 2010.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.